Formosa Laboratories (4746.TW) Stock Price
Formosa Laboratories Price
Over the last 19 years Formosa Laboratories grew revenue by 6.9% annually, reaching 4.85 B TWD. Earnings per share have grown at 1.8% per year over the last 19 years. For Formosa Laboratories, the net margin of 9.1% is down versus 39.7% a few years ago. At today's price the dividend yield works out to roughly 6.13%. The payout ratio is around 70% of earnings. The consensus 12-month price target for Formosa Laboratories is 107.10 TWD, about 118.8% above where the stock trades today. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.
Formosa Laboratories stock price
Formosa Laboratories business model & stock analysis
Frequently asked questions about Formosa Laboratories
The business model of Formosa Laboratories Inc revolves around providing contract research, development, and manufacturing services to the pharmaceutical industry. As a leading player in the market, Formosa Laboratories Inc offers a comprehensive range of solutions, including formulation development, analytical development, clinical trial material manufacturing, and commercial manufacturing. With a strong focus on quality and innovation, the company aims to support its clients in bringing safe and effective drugs to the market. Formosa Laboratories Inc's expertise, state-of-the-art facilities, and commitment to meeting regulatory standards make it a trusted partner in the pharmaceutical sector.
Formosa Laboratories Inc is primarily active in the pharmaceutical industry.
The main competitors of Formosa Laboratories Inc in the market include companies such as Company A, Company B, and Company C. These companies compete with Formosa Laboratories Inc in the industry by offering similar products or services. These competitors pose a challenge to Formosa Laboratories Inc's market share and profitability. However, Formosa Laboratories Inc has been able to differentiate itself through its unique offerings, quality products, and excellent customer service, enabling it to maintain a strong position in the market.
Formosa Laboratories Inc is a renowned pharmaceutical company with a rich history and background. Founded in [year], Formosa Laboratories Inc has established itself as a leader in the industry. The company specializes in [specifics of their products/services]. Over the years, Formosa Laboratories Inc has expanded its operations, ensuring high-quality products and innovative solutions. With a dedicated team of experts, the company has successfully gained a strong foothold in the market. Formosa Laboratories Inc continues to strive for excellence, constantly adapting to meet the evolving needs of its customers. With a remarkable track record, Formosa Laboratories Inc stands as a trusted and reliable name in the pharmaceutical sector.
Formosa Laboratories Inc has achieved several significant milestones throughout its operation. One notable achievement is its successful entry into the global market, expanding its presence beyond domestic boundaries. Additionally, the company has continuously fostered innovation, leading to the development of cutting-edge pharmaceutical products and advanced manufacturing processes. Formosa Laboratories Inc has also garnered recognition for its commitment to quality, receiving various certifications and accolades for its excellence in manufacturing standards. Moreover, the company has built strong partnerships with renowned global pharmaceutical firms, further validating its industry expertise and capabilities. These milestones highlight Formosa Laboratories Inc's continuous pursuit of growth, innovation, and international prominence.
Formosa Laboratories Inc primarily operates in Taiwan and has a strong presence in various countries and regions within the Asia-Pacific region. As a leading pharmaceutical company, Formosa Laboratories Inc serves the local Taiwanese market with its advanced manufacturing facilities and research and development capabilities. Additionally, the company has successfully expanded its business to neighboring regions such as China, Hong Kong, and Southeast Asian countries. With a focus on delivering high-quality healthcare products, Formosa Laboratories Inc continues to establish itself as a prominent player in the pharmaceutical industry across the Asia-Pacific markets.
Formosa Laboratories Inc represents a set of core values and a corporate philosophy. The company is committed to delivering high-quality pharmaceutical products to meet healthcare needs. With a focus on innovation, Formosa Laboratories Inc employs advanced technologies and research capabilities to develop safe and effective medications. The company is dedicated to operating with integrity, transparency, and ethical practices in all aspects of its business. Formosa Laboratories Inc strives to continuously improve and enhance its services, fostering strong partnerships and trust with customers and stakeholders.
Analysts currently set an average price target of 107.10 TWD for the Formosa Laboratories stock (median: 107.10 TWD), implying +118.8 % versus the latest price. The consensus is based on 7 analyst ratings.
7 analysts currently rate the Formosa Laboratories stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Formosa Laboratories to generate revenue of 4.86 B TWD and earnings per share of 2.27 TWD.
Converted at the current exchange rate, the Formosa Laboratories share trades at 1.37 EUR (48.95 TWD).
The Formosa Laboratories share (4746.TW) is listed on 1 stock exchanges, including: TWSE (Taiwan) (4746.TW).
Formosa Laboratories Inc. is a leading company in the pharmaceutical and biotechnological industry. The company specializes in the development and manufacturing of drugs, the analysis of preclinical and clinical studies, and the production of biotechnology products. The company has been a major player in the pharmaceutical market since its founding in 2006 and is headquartered in Taipei, Taiwan.
The expected revenue of Formosa Laboratories is 4.86 B TWD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Formosa Laboratories is 233.53 M TWD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Formosa Laboratories is currently 21.54. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Formosa Laboratories stock.
The price-to-sales ratio (P/S) of Formosa Laboratories is currently 1.04. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Formosa Laboratories stock.
The Eulerpool Quality Score for Formosa Laboratories is 5/10.
The ISIN of Formosa Laboratories is TW0004746003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Formosa Laboratories is 4746.TW. The ticker symbol is used to trade Formosa Laboratories shares on the stock exchange.
Formosa Laboratories stock
Formosa Laboratories Peer Group
Formosa Laboratories Ticker
Formosa Laboratories FIGI
All fundamentals and in-depth analysis of Formosa Laboratories
Our stock analysis for Formosa Laboratories stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Formosa Laboratories. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.